What would be your preferred treatment strategy for patients with NMIBC whose disease progresses after BCG plus durvalumab?
Will you continue with other intravesical therapies? Would there still be a future role for pembrolizumab for BCG-refractory disease in patients wishing to avoid radical cystectomy?
Community PollStarted
For a patient with high-risk NMIBC who progresses after BCG plus durvalumab, what would be your generally preferred next step?
12 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Urology · University of Washington School of Medicine
Answered on
Pembrolizumab is little used in real-world practice in 2026. The response rates were lower than those of other more recently available therapies for BCG-unresponsive high-risk CIS, and the risk/benefit tradeoff is less favorable than other newly available treatments. Most urologists would treat pati...
Join for free or sign in to see the full answer